Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 278

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Stroke Prevention Trial in Sickle Cell Anemia

Open access
Adams, Robert J, McKie, Virgil C, Brambilla, Don, Carl, Elizabeth, Gallagher, Dianne, Nichols, Fenwick T, Roach, Steve, Abboud, Miguel, Berman, Brian, Driscoll, Catherine, Files, Beatrice, Hsu, Lewis, Hurlet, Anne, Miller, Scott, Olivieri, Nancy, Pegelow, Charles, Scher, Charles, Vichinsky, Elliott, Wang, Winfred, Woods, Gerald, Kutlar, Abdullah, Wright, Elizabeth, Hagner, Susan, Tighe, Foss, Lewin, Jonathan, Cure, Joel, Zimmerman, Robert A, Waclawiw, Myron A·1998·Controlled Clinical Trials

Abstract

Stroke occurs in 7-8% of children with Sickle Cell Disease (Hb SS) and is a major cause of morbidity. Rates of recurrence have been reduced from 46-90% to less than 10% through chronic blood transfusions. Prevention of first stroke, however, would be preferable because even one stroke can cause irreversible brain injury. Transcranial Doppler (TCD) ultrasound can detect arterial blood flow rates associated with subsequent stroke risk. By combining TCD screening and a potentially effective treatment, first stroke may be prevented. The Stroke Prevention Trial in Sickle Cell Anemia (STOP) is the first stroke prevention trial in Hb SS and the first randomized, controlled use of transfusion in Hb SS. This multi-center trial is designed to test whether reducing sickle hemoglobin to 30% or less with periodic blood transfusions will reduce first-time stroke by at least 70% compared to standard care. Primary endpoints will be clinically evident symptoms of cerebral infarction with consistent findings on Magnetic Resonance Imaging and Angiography (MRI/MRA) or symptomatic intracranial hemorrhage. Secondary endpoints will be asymptomatic brain lesions detected by MRI in brain areas not involved in primary endpoints. The design calls for a 6-month start-up interval, 18 months of TCD screening and randomization, and observation for stroke from entry through month 54. Key features of the trial are standardized TCD and MRI/MRA protocols interpreted blindly, and blinded adjudication of endpoints. The sample size (60 per treatment group) is based on prospective data relating TCD velocity to risk of stroke. A time-averaged mean velocity of > or = 200 cm/sec is associated with a 46% risk of cerebral infarction over 39 months. The sample size is sufficient to detect 70% reduction in the primary endpoint at 90% power. This trial will determine if transfusion is effective in the primary prevention of stroke. Secondary aims may further the understanding of the effects of transfusion on the brain and guide future research into cerebrovascular disease in Hb SS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0197-2456(97)00099-8

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 278

Metadata

Authors
Adams, R. J., McKie, V. C., Brambilla, D., Carl, E., Gallagher, D., Nichols, F. T., Roach, S., Abboud, M., Berman, B., Driscoll, C., Files, B., Hsu, L., Hurlet, A., Miller, S., Olivieri, N., Pegelow, C., Scher, C., Vichinsky, E., Wang, W., Woods, G., Kutlar, A., Wright, E., Hagner, S., Tighe, F., Lewin, J., Cure, J., Zimmerman, R. A., & Waclawiw, M. A.
Venue
Controlled Clinical Trials
Publisher
Elsevier BV
Published
1998-02
Volume
19
Issue
1
Pages
110-129
ISSN
0197-2456 (ISSN-L)
OpenAlex
W1994951969
Cited by
278
References
18
FWCI
5.29
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stroke Prevention Trial in Sickle Cell Anemia. https://app.cochat.ai/papers/10.1016/s0197-2456(97)00099-8
The paper
Adams, R. J., McKie, V. C., Brambilla, D., Carl, E., Gallagher, D., Nichols, F. T., Roach, S., Abboud, M., Berman, B., Driscoll, C., Files, B., Hsu, L., Hurlet, A., Miller, S., Olivieri, N., Pegelow, C., Scher, C., Vichinsky, E., Wang, W., . . . Waclawiw, M. A. (1998). Stroke Prevention Trial in Sickle Cell Anemia. Controlled Clinical Trials. https://doi.org/10.1016/s0197-2456(97)00099-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.